ChemBriefGilead to Acquire PepStar's Inflammation Drug Program in $1.28 Billion Deal
Gilead Sciences agreed to acquire PepStar Therapeutics' oral inflammation drug program for $1.275 billion in cash. The deal adds HCXT-2001, an experimental treatment targeting the IL-23 pathway for in
reuters · 2026-10-22 13:12